OncLive TV

Stephanie Lee, MD, MPH, discusses 3-year follow-up data from the phase 3 ROCKstar Study of belumosudil in cGVHD.

Chul Kim, MD, MPH, discusses the impact of optimizing rare targets in lung cancer, highlighting the FDA approval of repotrectinib in ROS1-positive disease.

Neil D. Gross, MD, FACS, discusses a phase 2 study evaluating neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Dae Won Kim, MD, discusses findings from the NAPOLI 3 trial that support the use of NALIRIFOX in patients with metastatic pancreatic cancer.

Muhamad Alhaj Moustafa, MD, MS, discusses standard treatments for transplant-eligible and transplant-ineligible patients with mantle cell lymphoma.

Reshma Jagsi, MD, DPhil, discusses 5-year findings from the IDEA trial assessing radiotherapy omission for postmenopausal patients with breast cancer.

Chandler H. Park, MD, FACP, discusses the rationale for evaluating sacituzumab govitecan plus pembrolizumab in metastatic urothelial carcinoma.

Salman R. Punekar, MD, discusses the importance of complete biomarker testing and the landscape of biomarkers in lung cancer.

Michael J. Overman, MD, discusses the potential use of endoscopy and ctDNA to guide nonoperative management approaches in gastrointestinal cancers.

Anthony T. Nguyen, MD, PhD, discusses the role of concurrent chemotherapy with trimodal therapy in patients with muscle-invasive bladder cancer.

Brian I. Rini, MD, FASCO, discusses the research that led to the FDA approval of belzutifan for patients with advanced renal cell carcinoma.

Jonathon B. Cohen, MD, MS, discusses treatment considerations for mantle cell lymphoma and the role of pirtobrutinib in the management of this disease.

Federico Cappuzzo, MD, discusses findings from the phase 3 RATIONALE-315 trial in patients with resectable non–small cell lung cancer.

Jane L. Meisel, MD, discusses patient-reported perceptions of patient-provider communication in cancer care.

Jeffrey Zonder, MD, discusses the outcomes of the phase 3 PERSEUS trial in patients with relapsed/refractory multiple myeloma.

Jun Gong, MD, discusses the significance of the phase 3 EMBARK study of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

John M. Bryant, MD, discusses how identifying germline DNA repair mutations may impact the development of targeted therapy development in PDAC.

Chandler H. Park, MD, FACP, discusses the use of sacituzumab govitecan plus pembrolizumab in patients with metastatic urothelial carcinoma.

Kathryn Beckermann, MD, PhD, discusses the treatment of PY314 in combination with pembrolizumab in patients with clear cell renal cell carcinoma.

Eleonora Dondossola, PhD, discusses the importance of studying bone metastasis in RCC and other genitourinary cancers.

William B. Pearse, MD, discusses the significance of the ongoing phase 2 BOVen trial in TP53-mutant mantle cell lymphoma.

Pasi A. Jänne, MD, PhD, discusses the FDA approval of osimertinib plus chemotherapy in patients with EGFR-mutant locally advanced or metastatic NSCLC.

Rachid Baz, MD, discusses findings from an analysis of cytopenias and infections in patients with multiple myeloma enrolled in the KarMMa-3 trial.

Harriet Kluger, MD, discusses the FDA approval of the tumor infiltrating lymphocyte therapy lifileucel for patients with advanced melanoma.

Robert DeBernardo, MD, discusses the use of maintenance therapy in the second- and later-line settings for patients with ovarian cancer.

Jacob Shreve, MD, discusses the potential impact of implementing artificial intelligence into cancer care.

Abhishek Tripathi, MD, discusses the phase 1/2 NEMIO trial of durvalumab/chemotherapy with/without tremelimumab in muscle-invasive bladder cancer.

Pooja Advani, MBBS, MD, discusses the use of ribociclib plus endocrine therapy for patients with hormone receptor–positive, HER2– breast cancer.

Neal Shore, MD, FACS, discusses the implications of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.

Burton Eliot Appel, MD, discusses the significance of International Childhood Cancer Day.